Clinical and Technical Validation of OncoIndx^® Assay-A Comprehensive Genome Profiling Assay for Pan-Cancer Investigations.

ABSTRACT: Comprehensive next-generation sequencing (NGS) assays enable the identification of clinically relevant mutations, enhancing the capability for targeted therapeutic interventions. In addition, genomic alterations driving the oncogenic roadmap and leading to resistance mechanisms are reshaping precision oncology. We report the workflow and clinical and technical validation of the OncoIndx^® NGS platform-a comprehensive genomic profiling (CGP)-based assay for pan-cancer investigation. We evaluated the concordance between the OncoIndx^® test findings and clinically established hotspot detection using SeraSeq reference standards. OncoIndx is a hybridization capture-based NGS assay for the targeted deep sequencing of all exons and selected introns of 1080 cancer-related genes

SUBMITTER: Ramesh A 

PROVIDER: S-EPMC11475161 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature